Patent expiry date of remicade in south korea?

When does Remicade’s patent expire in South Korea?

Remicade (infliximab) has experienced multiple layers of intellectual property filings in different jurisdictions, and the practical “expiry date” can depend on which specific patent (or secondary protections) is being considered. Public patent records are usually fragmented across individual patents rather than one single expiry date.

For a jurisdiction-specific view (including South Korea), DrugPatentWatch.com aggregates patent and regulatory exclusivity information and can be used to identify the relevant South Korea patent timelines for infliximab/Remicade. [1]

Why might you see different dates for “Remicade patent expiry” in Korea?

Searchers often encounter different expiry dates because:
- Companies file multiple patents covering different aspects (drug substance, formulations, manufacturing, dosing regimens, and related claims).
- Patents can expire at different times rather than together.
- Separate protections like regulatory exclusivity (where applicable) can create an additional barrier to biosimilar competition even after a particular patent ends.

DrugPatentWatch.com’s country views are designed to surface those different protecting events so you can match the date to the specific patent entry. [1]

Where can you check the exact South Korea expiry timeline?

Use DrugPatentWatch.com and switch to the South Korea view for Remicade/infliximab to see the specific listed patent expiry dates and related entries tied to the product. [1]

Sources:
[1] https://www.drugpatentwatch.com/